

John G Gribben

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6465868/publications.pdf>

Version: 2024-02-01

579
papers

31,679
citations

2427

97
h-index

5539

163
g-index

588
all docs

588
docs citations

588
times ranked

25886
citing authors

#	ARTICLE	IF	CITATIONS
1	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. <i>ESMO Open</i> , 2022, 7, 100403.	4.5	32
2	Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). <i>Annals of Oncology</i> , 2022, 33, 259-275.	1.2	139
3	Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. <i>British Journal of Haematology</i> , 2022, 197, 82-96.	2.5	9
4	PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	14
5	Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment. <i>Science Signaling</i> , 2022, 15, eabl7989.	3.6	15
6	The role of BTK inhibitors on the tumor microenvironment in CLL. <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	1.3	2
7	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2022, 9, e374-e384.	4.6	11
8	B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities. <i>HemaSphere</i> , 2022, 6, e722.	2.7	6
9	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	2.7	1
10	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	512
11	Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. <i>Blood</i> , 2022, 140, 851-860.	1.4	28
12	CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	8
13	NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma. <i>Blood Advances</i> , 2022, 6, 5152-5159.	5.2	13
14	Retinoic acid-responsive CD8 effector T cells are selectively increased in IL-23-rich tissue in gastrointestinal GVHD. <i>Blood</i> , 2021, 137, 702-717.	1.4	6
15	Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways. <i>IScience</i> , 2021, 24, 102089.	4.1	14
16	DCE-MRI quantification of leukemia-induced changes in bone marrow vascular function. <i>Haematologica</i> , 2021, 106, 2281-2286.	3.5	0
17	KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. <i>Blood</i> , 2021, 138, 370-381.	1.4	33
18	Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients – a single centre experience. <i>British Journal of Haematology</i> , 2021, 193, 420-423.	2.5	2

#	ARTICLE	IF	CITATIONS
19	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	1.3	1
20	Integrated OMICs unveil the bone-marrow microenvironment in human leukemia. <i>Cell Reports</i> , 2021, 35, 109119.	6.4	14
21	Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. <i>Annals of Hematology</i> , 2021, 100, 1733-1742.	1.8	10
22	The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2021, 10, 4864-4873.	2.8	5
23	To start and stop or just keep going?. <i>Blood</i> , 2021, 138, 819-820.	1.4	0
24	Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1543-1565.	4.5	37
25	Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2021, 195, e131-e134.	2.5	2
26	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 2625-2636.	1.3	3
27	Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence. <i>Nature Communications</i> , 2021, 12, 5507.	12.8	15
28	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 5395.	12.8	15
29	Proteomics and Phospho-Proteomics Reveal Predictive Signatures of Response and Mechanisms of Resistance to Midostaurin Plus Chemotherapy in FLT3 Mutant Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3462-3462.	1.4	0
30	Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia. <i>Blood</i> , 2021, 138, 324-324.	1.4	0
31	Phosphoglycerate Dehydrogenase Is Required for Germinal Center Formation and Is a Therapeutic Target in MYC-driven Lymphoma. <i>Blood</i> , 2021, 138, 717-717.	1.4	0
32	A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL). <i>Blood</i> , 2021, 138, 3543-3543.	1.4	5
33	Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study. <i>Blood</i> , 2021, 138, 3726-3726.	1.4	3
34	Priming Death Receptor Mediated Apoptosis with Arginine Starvation Sensitises Arginine Auxotrophic B-ALL to CAR-T. <i>Blood</i> , 2021, 138, 2787-2787.	1.4	0
35	MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. <i>Leukemia</i> , 2020, 34, 522-532.	7.2	26
36	Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. <i>Haematologica</i> , 2020, 105, 1379-1390.	3.5	24

#	ARTICLE	IF	CITATIONS
37	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e50-e60.	4.6	53
38	Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 844-851.	2.5	19
39	Graft-versus-host disease: a case report of a rare but reversible cause of constrictive pericarditis. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-5.	0.6	0
40	Association of Low Tumor Endothelial Cell pY397 Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer. <i>JAMA Network Open</i> , 2020, 3, e2019304.	5.9	3
41	Clinical outcome of coronavirus disease 2019 in haematology patients. <i>British Journal of Haematology</i> , 2020, 190, e64-e67.	2.5	81
42	Cancer Burden Is Controlled by Mural Cell β 3-Integrin Regulated Crosstalk with Tumor Cells. <i>Cell</i> , 2020, 181, 1346-1363.e21.	28.9	53
43	Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative Phosphorylation. <i>Frontiers in Oncology</i> , 2020, 10, 307.	2.8	4
44	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , 2020, 105, e164-e168.	3.5	5
45	Stabilization of β -catenin upon B-cell receptor signaling promotes NF- κ B target genes transcription in mantle cell lymphoma. <i>Oncogene</i> , 2020, 39, 2934-2947.	5.9	15
46	Bone marrow niches in haematological malignancies. <i>Nature Reviews Cancer</i> , 2020, 20, 285-298.	28.4	270
47	Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?. <i>British Journal of Haematology</i> , 2020, 189, 603-604.	2.5	1
48	Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function. <i>Journal of Biological Chemistry</i> , 2020, 295, 5496-5508.	3.4	6
49	IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. <i>Blood</i> , 2020, 135, 834-844.	1.4	23
50	Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. <i>Bone Marrow Transplantation</i> , 2020, 55, 1840-1843.	2.4	3
51	Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2020, 130, 3038-3050.	8.2	48
52	Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. <i>Blood</i> , 2020, 136, 37-39.	1.4	37
53	Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. <i>Blood</i> , 2020, 136, 17-18.	1.4	11
54	Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 8023-8023.	1.6	9

#	ARTICLE	IF	CITATIONS
55	Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings. <i>Blood</i> , 2020, 136, 37-38.	1.4	3
56	Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Unstable Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 12-13.	1.4	0
57	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2722-2729.	1.6	197
58	Phenotypic characterisation of regulatory T cells in dogs reveals signature transcripts conserved in humans and mice. <i>Scientific Reports</i> , 2019, 9, 13478.	3.3	17
59	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. <i>Nature</i> , 2019, 570, 474-479.	27.8	86
60	Autologous stem cell transplantation in refractory Crohn's disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. <i>BMC Gastroenterology</i> , 2019, 19, 82.	2.0	17
61	Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation. <i>Cell Reports</i> , 2019, 27, 1461-1471.e4.	6.4	17
62	Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma. <i>Cell Death and Disease</i> , 2019, 10, 330.	6.3	29
63	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2765-2775.	1.4	63
64	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199.	1.6	277
65	Here to Stay: Biosimilars in Hematology. <i>HemaSphere</i> , 2019, 3, e323.	2.7	2
66	A randomized pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling during surgery. <i>Pain</i> , 2019, 160, 2691-2698.	4.2	11
67	Single cell analysis of clonal architecture in acute myeloid leukaemia. <i>Leukemia</i> , 2019, 33, 1113-1123.	7.2	65
68	Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy. <i>Haematologica</i> , 2019, 104, e42-e44.	3.5	6
69	The E1/4-TCL1 Mouse Model of Chronic Lymphocytic Leukemia. , 2019, , 1-29.		0
70	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	1.3	6
71	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 43-56.	10.7	448
72	Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2019, 134, 347-347.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadalim Study. <i>Blood</i> , 2019, 134, 2822-2822.	1.4	3
74	Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017. <i>Blood</i> , 2019, 134, 4575-4575.	1.4	3
75	Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2019, 134, 324-324.	1.4	2
76	The E1/4-TCL1 Mouse Model of Chronic Lymphocytic Leukemia. , 2019, , 2213-2241.		0
77	SAT-LB056 Is AIP a Tumor Suppressor or an Oncogene? AIP as a Novel Regulator of the Oncogene BCL6 in Diffuse Large B Cell Lymphoma. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
78	Efficacy and time to next treatment following lenalidomide/rituximab (R²) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7514-7514.	1.6	0
79	CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS. <i>Blood</i> , 2019, 134, 249-249.	1.4	0
80	The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets. <i>Blood</i> , 2019, 134, 5240-5240.	1.4	0
81	CRISPR/Cas9-Targeted De Novo DNA Methylation Is Maintained and Impacts the Colony Forming Potential of Human Hematopoietic CD34+ Cells. <i>Blood</i> , 2019, 134, 2517-2517.	1.4	1
82	Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel. <i>Blood</i> , 2019, 134, 2769-2769.	1.4	0
83	Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment. <i>Blood</i> , 2019, 134, 658-658.	1.4	2
84	Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT. <i>Blood</i> , 2019, 134, 595-595.	1.4	1
85	Treatment with Acalabrutinib, Ibrutinib and CD19 CAR T Cells Restore the Number of Granulocytic Myeloid Derived Suppressor Cells in CLL-Bearing Mice. <i>Blood</i> , 2019, 134, 3032-3032.	1.4	1
86	Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. <i>Leukemia</i> , 2018, 32, 1818-1822.	7.2	36
87	Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. <i>Leukemia</i> , 2018, 32, 1261-1265.	7.2	87
88	Acute myeloid leukemia xenograft success prediction: Saving time. <i>Experimental Hematology</i> , 2018, 59, 66-71.e4.	0.4	16
89	Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. <i>British Journal of Haematology</i> , 2018, 180, 666-679.	2.5	51
90	Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. <i>Haematologica</i> , 2018, 103, 688-697.	3.5	26

#	ARTICLE	IF	CITATIONS
91	Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. <i>Cancer Discovery</i> , 2018, 8, 304-319.	9.4	255
92	Durable graft-versus-leukaemia effects without donor lymphocyte infusions – results of a phase 2 study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia. <i>British Journal of Haematology</i> , 2018, 180, 346-355.	2.5	4
93	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1530-1542.	10.7	91
94	Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD4+ Low Intensity Therapy Evaluation Study Investigators. <i>Frontiers in Immunology</i> , 2018, 9, 646.	4.8	25
95	How and when I do allogeneic transplant in CLL. <i>Blood</i> , 2018, 132, 31-39.	1.4	49
96	No longer too exhausted to run. <i>Blood</i> , 2018, 132, 464-465.	1.4	2
97	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410.	4.1	24
98	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2018, 5, e563-e598.	4.6	97
99	Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. <i>Blood</i> , 2018, 132, 182-182.	1.4	20
100	AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 445-445.	1.4	9
101	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. <i>Blood</i> , 2018, 132, 5565-5565.	1.4	3
102	Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 ILLUMINATE. <i>Blood</i> , 2018, 132, 691-691.	1.4	8
103	A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies. <i>Blood</i> , 2018, 132, 4161-4161.	1.4	3
104	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 4196-4196.	1.4	16
105	Characterising the Immunological Microenvironment in Newly Diagnosed Multiple Myeloma Bone Marrow By Time of Flight Cytometry Reveals Abnormalities in Antigen Presenting and Effector Lymphocyte Populations with Prognostic Significance. <i>Blood</i> , 2018, 132, 58-58.	1.4	2
106	Immune Microenvironment Analysis of Bone Marrow By Mass Cytometry and RNA Sequencing in Multiple Myeloma Patients Treated with Daratumumab and Durvalumab. <i>Blood</i> , 2018, 132, 3296-3296.	1.4	1
107	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018, 132, 4097-4097.	1.4	5
108	Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study. <i>Blood</i> , 2018, 132, 1597-1597.	1.4	13

#	ARTICLE	IF	CITATIONS
109	Modulation of T-Cell Function in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Btki Appears Independent of ITK. <i>Blood</i> , 2018, 132, 3139-3139.	1.4	1
110	The Treg/Th17 Axis Is Skewed in Classical Hodgkin Lymphoma By PDL1+Ve but Not PDL1-Ve Lymphoma Cells and By Lymphoma MHC Class 2 Expression.. <i>Blood</i> , 2018, 132, 4124-4124.	1.4	0
111	Anti-CD20 Monoclonal Antibodies Hijack the B-Cell Receptor Signaling Cascade Thereby Activating the NOTCH1 Signaling Pathway. <i>Blood</i> , 2018, 132, 588-588.	1.4	0
112	Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial. <i>Blood</i> , 2018, 132, 4419-4419.	1.4	0
113	Immunoglobulin Variable Region Gene Sequences Reveal N-Glycosylation Motifs As an Early and Stable Event in Follicular Lymphoma Pathology. <i>Blood</i> , 2018, 132, 4101-4101.	1.4	0
114	Deep Phenotypic Analysis Reveals a Monocyte Subpopulation Predictive of Relapse/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 2863-2863.	1.4	0
115	Modulation of T-Cell Function and Immune Phenotype in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Ibrutinib. <i>Blood</i> , 2018, 132, 3138-3138.	1.4	0
116	B-Cell Receptor Signaling Drives Glycolysis in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2018, 132, 3121-3121.	1.4	0
117	Exhausted CLL T Cells Mediated By PD1 Expression an Important Mechanism for CD19 CAR Efficacy in CLL in the Adoptive Transfer TCL1 Mouse Model. <i>Blood</i> , 2018, 132, 4537-4537.	1.4	0
118	Chronic lymphocytic leukaemia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 16096.	30.5	363
119	Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). <i>Leukemia</i> , 2017, 31, 1240-1243.	7.2	26
120	Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. <i>Leukemia</i> , 2017, 31, 2085-2093.	7.2	27
121	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	3.5	39
122	Restoring leukemia cell function from the inside out. <i>Blood</i> , 2017, 129, 3137-3138.	1.4	0
123	The role of stem cell transplant for lymphoma in 2017. <i>Hematological Oncology</i> , 2017, 35, 25-29.	1.7	7
124	Follicular lymphoma: State of the Art ICML workshop in Lugano 2015. <i>Hematological Oncology</i> , 2017, 35, 397-407.	1.7	11
125	Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors. <i>Supportive Care in Cancer</i> , 2017, 25, 739-748.	2.2	5
126	Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. <i>Leukemia</i> , 2017, 31, 734-738.	7.2	18

#	ARTICLE	IF	CITATIONS
127	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. <i>Annals of Hematology</i> , 2017, 96, 253-259.	1.8	22
128	Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition. <i>Oncogene</i> , 2017, 36, 2762-2774.	5.9	24
129	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. <i>Cell</i> , 2017, 171, 481-494.e15.	28.9	804
130	Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2017, 32, 324-341.e6.	16.8	179
131	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 399-406.	8.1	70
132	Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. <i>Leukemia</i> , 2017, , .	7.2	0
133	The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. <i>Nature Communications</i> , 2017, 8, 1679.	12.8	36
134	Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia. <i>Journal of Oncology Practice</i> , 2017, 13, 371-377.	2.5	16
135	Versatile humanized niche model enables study of normal and malignant human hematopoiesis. <i>Journal of Clinical Investigation</i> , 2017, 127, 543-548.	8.2	82
136	Aberrant Immunological Synapses Driven by Leukemic Antigen-Presenting Cells. <i>Methods in Molecular Biology</i> , 2017, 1584, 533-544.	0.9	0
137	Human Gastro-Intestinal Graft-Versus-Host Disease Is Mediated By Retinoic Acid-Responsive CD8+ Effector T-Cells Under IL-23 Polarising Conditions. <i>Blood</i> , 2017, 130, 77-77.	1.4	0
138	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 2931-2940.	1.4	102
139	Obinutuzumab for the treatment of indolent lymphoma. <i>Future Oncology</i> , 2016, 12, 1769-1781.	2.4	8
140	Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 29-36.	2.3	23
141	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. <i>Leukemia and Lymphoma</i> , 2016, 57, 1291-1299.	1.3	17
142	Allospecific Tregs Expanded After Anergization Remain Suppressive in Inflammatory Conditions but Lack Expression of Gut-homing Molecules. <i>Molecular Therapy</i> , 2016, 24, 1126-1134.	8.2	1
143	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. <i>Haematologica</i> , 2016, 101, 531-540.	3.5	75
144	TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. <i>Blood</i> , 2016, 128, 72-81.	1.4	29

#	ARTICLE	IF	CITATIONS
145	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. <i>Haematologica</i> , 2016, 101, 1144-1158.	3.5	6
146	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87
147	Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 989-998.	2.4	26
148	Characteristics of human primary mantle cell lymphoma engraftment in NSG mice. <i>British Journal of Haematology</i> , 2016, 173, 165-169.	2.5	3
149	<scp>NCRI</scp> phase <scp>II</scp> study of <scp>CHOP</scp> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. <i>British Journal of Haematology</i> , 2016, 175, 43-54.	2.5	53
150	T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. <i>Nature</i> , 2016, 538, 518-522.	27.8	159
151	RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. <i>Nature Immunology</i> , 2016, 17, 1352-1360.	14.5	115
152	Stem Cell Transplantation for Refractory Crohn Diseaseâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2620.	7.4	9
153	Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1081-1093.	10.7	297
154	Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. <i>Blood Cancer Journal</i> , 2016, 6, e404-e404.	6.2	14
155	Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients. <i>Cancer Research</i> , 2016, 76, 2082-2086.	0.9	24
156	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. <i>Nature Genetics</i> , 2016, 48, 183-188.	21.4	160
157	Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. <i>Leukemia</i> , 2016, 30, 570-579.	7.2	102
158	Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups. <i>Blood</i> , 2016, 128, 1087-1087.	1.4	4
159	Reduction of Mitochondrial Membrane Potential Leads to Enhancement of Type-II CD20-Antibody Cytotoxicity in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1763-1763.	1.4	1
160	Proteomic Analysis Directs Effective Drug Selection in Relapsed AML By Quantifying Drug Targets. <i>Blood</i> , 2016, 128, 5265-5265.	1.4	1
161	Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. <i>Blood</i> , 2016, 128, 615-615.	1.4	22
162	Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia. <i>Current Cancer Drug Targets</i> , 2016, 16, 689-700.	1.6	20

#	ARTICLE	IF	CITATIONS
163	Differentiation Status Revealed By Shotgun Phosphoproteomics Determines Sensitivity of Primary AML Cells to Kinase Inhibitors. <i>Blood</i> , 2016, 128, 840-840.	1.4	0
164	Allresponses of Human T-Cells from Adult Peripheral Blood and Umbilical Cord Blood Are Differentially Impacted By Lenalidomide. <i>Blood</i> , 2016, 128, 5714-5714.	1.4	0
165	Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment. <i>Blood</i> , 2016, 128, 5199-5199.	1.4	1
166	In Chronic Lymphocytic Leukemia \hat{I} CT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation. <i>Blood</i> , 2016, 128, 971-971.	1.4	8
167	Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC \hat{A} subversion induces up-regulation of PKC \hat{A} II expression in B lymphocytes. <i>Haematologica</i> , 2015, 100, 499-510.	3.5	8
168	Disease evolution and outcomes in familial AML with germline CEBPA mutations. <i>Blood</i> , 2015, 126, 1214-1223.	1.4	157
169	Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. <i>Blood</i> , 2015, 125, 4060-4068.	1.4	105
170	Mechanisms of PD-L1/PD-1 \hat{A} mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E \hat{A} -TCL1 CLL mouse model. <i>Blood</i> , 2015, 126, 212-221.	1.4	111
171	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. <i>Leukemia and Lymphoma</i> , 2015, 56, 3031-3037.	1.3	9
172	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2524.	7.4	136
173	Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. <i>Haematologica</i> , 2015, 100, 363-369.	3.5	53
174	Enhanced Activation of an Amino-Terminally Truncated Isoform of Voltage-Gated Proton Channel HVCN1 Enriched in Malignant B cells. <i>Biophysical Journal</i> , 2015, 108, 20a.	0.5	0
175	Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2803-2811.	1.6	231
176	Empirical inference of circuitry and plasticity in a kinase signaling network. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7719-7724.	7.1	69
177	The role of the tumor microenvironment in HIV-associated lymphomas. <i>Biomarkers in Medicine</i> , 2015, 9, 473-482.	1.4	14
178	PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 203-211.	1.4	158
179	XV. Clinical aspects of transformed lymphoma. <i>Hematological Oncology</i> , 2015, 33, 80-83.	1.7	1
180	Microenvironment abnormalities and lymphomagenesis: Immunological aspects. <i>Seminars in Cancer Biology</i> , 2015, 34, 36-45.	9.6	29

#	ARTICLE	IF	CITATIONS
181	Inhibitors of <sc>BCR</sc> signalling interrupt the survival signal mediated by the microenvironment in mantle cell lymphoma. <i>International Journal of Cancer</i> , 2015, 136, 2761-2774.	5.1	47
182	Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 1532-1532.	1.4	5
183	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1713-1713.	1.4	1
184	Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 3978-3978.	1.4	17
185	Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331). <i>Blood</i> , 2015, 126, 494-494.	1.4	23
186	Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2514-2514.	1.6	5
187	A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2547-2547.	1.6	3
188	GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA8502-LBA8502.	1.6	10
189	High Throughput Sequencing Analysis of the Immunoglobulin Heavy Chain Gene from Flow-Sorted B Cell Sub-Populations Define the Dynamics of Follicular Lymphoma Clonal Evolution. <i>PLoS ONE</i> , 2015, 10, e0134833.	2.5	28
190	Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 27816-27831.	1.8	20
191	GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA8502-LBA8502.	1.6	2
192	Overexpression of HMGB1 Receptor RAGE Is Associated with Worse Clinical Outcome in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 617-617.	1.4	0
193	New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 586-94.	0.3	4
194	Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors. <i>British Journal of Haematology</i> , 2014, 164, 790-803.	2.5	35
195	Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. <i>British Journal of Haematology</i> , 2014, 164, 526-535.	2.5	53
196	Transplantation in Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1055-1071.	2.2	2
197	Primary refractory <sc>T</sc>-cell polymphocytic leukaemia treated with daily administration of <sc>A</sc>-lemtuzumab plus high-dose methylprednisolone. <i>European Journal of Haematology</i> , 2014, 92, 360-361.	2.2	5
198	Cutaneous cryptococcosis in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 164, 467-467.	2.5	5

#	ARTICLE	IF	CITATIONS
199	Parenthood in long-term survivors after <scp>CHOP</scp> with or without etoposide treatment for aggressive lymphoma—Response to Meissner <i>et al</i>. <i>British Journal of Haematology</i> , 2014, 166, 615-616.	2.5	1
200	Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18078-18083.	7.1	74
201	The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma. <i>Nuclear Medicine Communications</i> , 2014, 35, 311-315.	1.1	15
202	Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. <i>Cancer Genetics</i> , 2014, 207, 19-30.	0.4	5
203	The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies. <i>Seminars in Cancer Biology</i> , 2014, 24, 71-81.	9.6	242
204	Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 1709-1719.	1.4	95
205	Immunomodulation and Immune Reconstitution in Chronic Lymphocytic Leukemia. <i>Seminars in Hematology</i> , 2014, 51, 228-234.	3.4	43
206	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. <i>Nature Genetics</i> , 2014, 46, 176-181.	21.4	624
207	A Niche-Like Culture System Allowing the Maintenance of Primary Human Acute Myeloid Leukemia-Initiating Cells: A New Tool to Decipher Their Chemoresistance and Self-Renewal Mechanisms. <i>Stem Cells Translational Medicine</i> , 2014, 3, 520-529.	3.3	95
208	Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. <i>Blood</i> , 2014, 123, 2066-2074.	1.4	39
209	Immune Responses and Outcome in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1757-1759.	1.6	3
210	Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence?. <i>Genomics</i> , 2014, 104, 352-357.	2.9	100
211	Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. <i>Nature</i> , 2014, 514, 112-116.	27.8	137
212	Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1236-1241.	1.6	109
213	The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2014, 99, 715-725.	3.5	52
214	Hanging tough: CMV-specific CD8+ T cells in CLL. <i>Blood</i> , 2014, 123, 608-609.	1.4	2
215	Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. <i>Blood</i> , 2014, 123, 4101-4110.	1.4	63
216	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 42-48.	1.4	60

#	ARTICLE	IF	CITATIONS
217	Dangerous power: mitochondria in CLL cells. <i>Blood</i> , 2014, 123, 2596-2597.	1.4	5
218	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. <i>Blood</i> , 2014, 124, 3841-3849.	1.4	185
219	TNFRSF14 aberrations in Follicular Lymphoma B Cells Result in Increased Alloresponses in Vitro and in Vivo. <i>Blood</i> , 2014, 124, 2426-2426.	1.4	1
220	Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2. <i>Oncotarget</i> , 2014, 5, 11653-11668.	1.8	22
221	AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8614-TPS8614.	1.6	0
222	Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model. <i>Blood</i> , 2014, 124, 3298-3298.	1.4	0
223	Late Effects: An Evaluation of Contrasting Physical and Psychological Experiences Between Child and Adult Hodgkin Survivors. <i>Blood</i> , 2014, 124, 1309-1309.	1.4	0
224	SKIP Is Underexpressed in AML Leading to Sphingosine Kinase Hypofunction. <i>Blood</i> , 2014, 124, 5324-5324.	1.4	1
225	Aberrant PD-L1 Expression in CLL As a Result of Adaptive Immune Resistance Mediated By Tumor-Secreted Circulating miRNA Binding to Toll-like Receptor 7. <i>Blood</i> , 2014, 124, 716-716.	1.4	0
226	The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in E μ -TCL1 Mice By Targeting Aberrant TNF Receptor Signaling. <i>Blood</i> , 2014, 124, 1966-1966.	1.4	0
227	High Resolution Genomic Profiling of Primary "Ultra High Risk" and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. <i>Blood</i> , 2014, 124, 3288-3288.	1.4	0
228	Immune Checkpoint Blockade with Anti-PD-L1 Prevents Immune Dysfunction and CLL Development in the TCL1 Adoptive Transfer Mouse Model. <i>Blood</i> , 2014, 124, 717-717.	1.4	0
229	Overexpression of BCL-2 Does Not Inhibit Autophagy in Human Follicular and Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2014, 124, 3007-3007.	1.4	12
230	Lenalidomide Enhances Human Alloresponses By Increasing Proliferation of Effector Memory CD8 T Cells with Enhanced Polyfunctional Effector Capacity and a Unique Gene Expression Profile. <i>Blood</i> , 2014, 124, 1103-1103.	1.4	0
231	Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 207-235.	2.2	84
232	HIF-2 β Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress. <i>Cell Stem Cell</i> , 2013, 13, 549-563.	11.1	163
233	Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. <i>Blood</i> , 2013, 122, 2856-2863.	1.4	148
234	Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13576-13581.	7.1	120

#	ARTICLE	IF	CITATIONS
235	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	1.2	193
236	Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion. <i>British Journal of Haematology</i> , 2013, 162, 525-529.	2.5	11
237	Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. <i>Histopathology</i> , 2013, 62, 860-875.	2.9	32
238	Follicular Lymphoma Cells Induce Changes in T-Cell Gene Expression and Function: Potential Impact on Survival and Risk of Transformation. <i>Journal of Clinical Oncology</i> , 2013, 31, 2654-2661.	1.6	101
239	EZH2 mutations are frequent and represent an early event in follicular lymphoma. <i>Blood</i> , 2013, 122, 3165-3168.	1.4	274
240	Immunotherapeutic strategies including transplantation: eradication of disease. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 151-157.	2.5	13
241	Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies. <i>Clinical Cancer Research</i> , 2013, 19, 6686-6695.	7.0	115
242	Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. <i>Haematologica</i> , 2013, 98, 620-625.	3.5	12
243	Reverse-engineering the genetic circuitry of a cancer cell with predicted intervention in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 459-464.	7.1	23
244	Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. <i>Leukemia</i> , 2013, 27, 362-369.	7.2	95
245	Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. <i>Blood</i> , 2013, 121, 2704-2714.	1.4	116
246	T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. <i>Blood</i> , 2013, 121, 1612-1621.	1.4	422
247	The role of B7 family molecules in hematologic malignancy. <i>Blood</i> , 2013, 121, 734-744.	1.4	159
248	p110 δ -mediated constitutive PI3K signaling limits the efficacy of p110 δ -selective inhibition in mantle cell lymphoma, particularly with multiple relapse. <i>Blood</i> , 2013, 121, 2274-2284.	1.4	116
249	A shot in the arm for radiotherapy. <i>Blood</i> , 2013, 121, 246-248.	1.4	0
250	Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. <i>PLoS ONE</i> , 2013, 8, e76781.	2.5	155
251	Arginine Deprivation With Pegylated Arginine Deiminase Induces Death Of Acute Myeloid Leukaemia Cells In Vivo. <i>Blood</i> , 2013, 122, 1458-1458.	1.4	1
252	T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 Subsets and This Can Be Further Promoted By Ibrutinib Treatment. <i>Blood</i> , 2013, 122, 4120-4120.	1.4	3

#	ARTICLE	IF	CITATIONS
253	Concurrent Follicular Lymphoma At Diagnosis Has a Negative Impact On The Outcome Of Patients With Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2013, 122, 4260-4260.	1.4	3
254	Psychosocial Factors and Impact Of Cancer In British Long-Term Haematological Cancer Survivors. <i>Blood</i> , 2013, 122, 2943-2943.	1.4	28
255	Loss of Imprinting at the 14q32 Domain Leads to MicroRNA Overexpression in Acute Promyelocytic Leukemia. <i>Blood</i> , 2013, 122, 2494-2494.	1.4	0
256	NK Cells From CLL Patients Exhibit Down-Regulation Of Interferon Response Genes That Can Be Reversed With Lenalidomide. <i>Blood</i> , 2013, 122, 4131-4131.	1.4	1
257	Intraclonal Complexity Of CLL Fractions In Cell Proliferation Rates, Gene Expression Signatures, and Responses To Autologous T-Cell Help In Peripheral blood and Secondary Lymphoid Tissues. <i>Blood</i> , 2013, 122, 115-115.	1.4	0
258	Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility. <i>Blood</i> , 2013, 122, 4159-4159.	1.4	0
259	Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemia. <i>Discovery Medicine</i> , 2013, 16, 295-302.	0.5	5
260	Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 3389-3398.	1.9	19
261	Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. <i>Blood</i> , 2012, 120, 1412-1421.	1.4	320
262	Risk categories and refractory CLL in the era of chemoimmunotherapy. <i>Blood</i> , 2012, 119, 4101-4107.	1.4	107
263	Less expensive CARs?. <i>Cytotherapy</i> , 2012, 14, 773-774.	0.7	1
264	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 417-423.	1.3	56
265	Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. <i>Leukemia and Lymphoma</i> , 2012, 53, 1743-1748.	1.3	16
266	Blocking Autophagy Prevents Bortezomib-Induced NF- κ B Activation by Reducing I- κ B α Degradation in Lymphoma Cells. <i>PLoS ONE</i> , 2012, 7, e32584.	2.5	87
267	Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC. <i>PLoS ONE</i> , 2012, 7, e51390.	2.5	9
268	Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 2483-2491.	1.6	120
269	Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT. <i>European Journal of Haematology</i> , 2012, 89, 206-213.	2.2	20
270	Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis. <i>British Journal of Haematology</i> , 2012, 157, 201-204.	2.5	9

#	ARTICLE	IF	CITATIONS
271	Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract. British Journal of Haematology, 2012, 157, 403-407.	2.5	18
272	Cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies. British Journal of Haematology, 2012, 157, 580-585.	2.5	7
273	Immune Reconstitution in Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports, 2012, 7, 13-20.	2.3	23
274	Human Primary Mantle Cell Lymphoma Can Be Established in NOD/SCID/IL2R β -Null Mice. Blood, 2012, 120, 1565-1565.	1.4	1
275	Increased Tonic PI3K Signaling Through p110 α Can Limit the Efficacy of PI3K-Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse. Blood, 2012, 120, 1652-1652.	1.4	1
276	IL-6, IL-8 and VEGF Neutralisation Restores Drug Sensitivity to Conventional and Novel Treatment Combinations in a Multiple Myeloma Bone Marrow Micro-Environment Model. Blood, 2012, 120, 2949-2949.	1.4	1
277	Transplant in Chronic Lymphocytic Leukemia: To Do It or Not and If So, When and How?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 399-404.	3.8	0
278	Genetics of Teenage and Young Adult Acute Lymphoblastic T-Cell Leukaemia. Blood, 2012, 120, 2521-2521.	1.4	0
279	High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. Blood, 2012, 120, 545-545.	1.4	0
280	Characterizing Immunophenotypic and Functional Pseudo-Exhaustion in T Cells From CLL Patients: The Impact of Lenalidomide. Blood, 2012, 120, 564-564.	1.4	0
281	The Clinical Course of Patients with Follicular Lymphoma in the Rituximab Era: A Paradigm Shift. Blood, 2012, 120, 1580-1580.	1.4	1
282	Assessment of Bone Marrow Involvement by FDG-PET in Patients with Follicular Lymphoma. Blood, 2012, 120, 5108-5108.	1.4	0
283	Inhibition of Autophagy by Chloroquine Sensitises Lymphoma Cells to ABT-737-Induced Apoptosis. Blood, 2012, 120, 1625-1625.	1.4	1
284	Anergic Response to B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: The Differing Roles of IgD and IgM in the Microenvironment and Peripheral Blood. Blood, 2012, 120, 2889-2889.	1.4	1
285	Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma. Blood, 2012, 120, 145-145.	1.4	0
286	HMGB1 Activates TLR9/RAGE Signalling Pathway and Sustains Chronic Lymphocytic Leukemic Cell in Vitro Survival. Blood, 2012, 120, 3860-3860.	1.4	1
287	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. Blood, 2012, 120, 3865-3865.	1.4	0
288	Impact of Tumor Infiltrating T Cells in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1572-1572.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On E μ 4-TCL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo. <i>Blood</i> , 2012, 120, 313-313.	1.4	1
290	The Relationship of Depression and Anxiety and Impact of Cancer in Long-Term Survivors of Haematological Malignancy.. <i>Blood</i> , 2012, 120, 3174-3174.	1.4	0
291	The Diffuse Large B-Cell Lymphoma Infiltrating Macrophage Transcriptome Signature Is Enriched for Both M1 and M2 Genes and Provides an Excellent Platform for Functional Validation of Macrophage Biology in DLBCL. <i>Blood</i> , 2012, 120, 790-790.	1.4	1
292	2.17 Activation of STAT3 Increases Mitochondrial Respiration and Protects Mitochondria from Oxidative Damage in Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S170-S171.	0.4	0
293	2.46 Signal Transducer and Activator of Transcription 3 and Nuclear Factor κ B Activation Regulate Autocrine Interleukin-6 Production and Indicate the Prognosis of CLL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S188-S189.	0.4	0
294	Stem Cell Transplantation for Indolent Lymphoma and Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S63-S70.	2.0	17
295	Autografting CLL: the game is over!. <i>Blood</i> , 2011, 117, 6057-6058.	1.4	12
296	SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. <i>Blood</i> , 2011, 117, 3147-3150.	1.4	17
297	A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, e1-e15.	1.4	22
298	The kiss of death in FL. <i>Blood</i> , 2011, 118, 5365-5366.	1.4	3
299	EZH2 Y641 mutations in follicular lymphoma. <i>Leukemia</i> , 2011, 25, 726-729.	7.2	132
300	Chronic Lymphocytic Leukemia: An Update on Biology and Treatment. <i>Current Oncology Reports</i> , 2011, 13, 379-85.	4.0	15
301	Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2011, 117, 116-124.	4.1	17
302	Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. <i>Journal of Clinical Oncology</i> , 2011, 29, 1349-1355.	1.6	124
303	Demonstration of Durable Graft Versus Lymphoma Effects in Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 952-953.	1.6	5
304	Update on Therapy of Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 544-550.	1.6	102
305	The PD1/PD-L1 Axis in the Classical Hodgkin Lymphoma Microenvironment: PD-1 Is Rarely Expressed but Identifies Patients with High-Risk Disease. <i>Blood</i> , 2011, 118, 1560-1560.	1.4	6
306	PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110 α -Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients. <i>Blood</i> , 2011, 118, 1654-1654.	1.4	1

#	ARTICLE	IF	CITATIONS
307	Manipulating Tumor Associated Macrophages (TAM) in a Mouse Model of B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011, 118, 1657-1657.	1.4	2
308	Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 1794-1794.	1.4	2
309	CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 246-246.	1.4	1
310	Activation of Mitochondrial STAT3 Increases Mitochondrial Respiration and Inhibits Oxidative Stress in Chronic Lymphocytic Leukemic Cells. <i>Blood</i> , 2011, 118, 287-287.	1.4	2
311	Exploring the Immune Microenvironment of Diffuse Large B Cell Lymphoma in a Tissue Microarray: Predicting Survival with a Score That Incorporates Macrophages, Cytotoxic and Regulatory T Cells. <i>Blood</i> , 2011, 118, 951-951.	1.4	1
312	Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 976-976.	1.4	2
313	T-Cells From Patients with CLL Exhibit Phenotypic and Transcription Factor Profiles of Exhaustion Independent of CMV Serostatus. <i>Blood</i> , 2011, 118, 1780-1780.	1.4	0
314	HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era,. <i>Blood</i> , 2011, 118, 3646-3646.	1.4	0
315	Impact of Tumor Infiltrating T Cells in Patients with Follicular Lymphoma At Diagnosis. <i>Blood</i> , 2011, 118, 769-769.	1.4	0
316	Chronic Lymphocytic Leukemia Cells Co-Opt CD200, CD270, CD274 and CD276 to Induce Impaired Actin Polarization At the T Cell Immune Synapse. <i>Blood</i> , 2011, 118, 802-802.	1.4	0
317	The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party. <i>Blood</i> , 2011, 118, 502-502.	1.4	1
318	Continuous CD4+ T Cell Lines Derived From the Classical Hodgkin Lymphoma Microenvironment: A Challenge to the Assumption of Anergy,. <i>Blood</i> , 2011, 118, 3645-3645.	1.4	24
319	Neither the FLIPI Nor the FLIPI2 Accurately Segregates Low- Risk From Intermediate- Risk Follicular Lymphoma Patients in Terms of Progression-Free Survival. <i>Blood</i> , 2011, 118, 2663-2663.	1.4	0
320	Autocrine IL-6 Production Indicates the Level of Activated STAT3 and NF-Kb of Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 1784-1784.	1.4	3
321	Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Exvivo Expansion. <i>Journal of Immunotherapy</i> , 2010, 33, 684-696.	2.4	58
322	Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. <i>Current Opinion in Oncology</i> , 2010, 22, 424-430.	2.4	29
323	Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34 ^{hi} fraction. <i>Blood</i> , 2010, 115, 1976-1984.	1.4	315
324	CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 3079-3088.	1.4	48

#	ARTICLE	IF	CITATIONS
325	GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. <i>Blood</i> , 2010, 115, 3939-3948.	1.4	107
326	Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. <i>Blood</i> , 2010, 115, 5053-5056.	1.4	113
327	The 3 Rs in CLL immune dysfunction. <i>Blood</i> , 2010, 115, 2563-2564.	1.4	3
328	T-cell function in chronic lymphocytic leukaemia. <i>Seminars in Cancer Biology</i> , 2010, 20, 431-438.	9.6	44
329	Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia. <i>Blood Reviews</i> , 2010, 24, 135-141.	5.7	13
330	The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia – CXCR4 antagonists as potential adjuvants for monoclonal antibodies. <i>British Journal of Haematology</i> , 2010, 151, 167-178.	2.5	30
331	Targeting the microenvironment. <i>Leukemia and Lymphoma</i> , 2010, 51, 34-40.	1.3	12
332	Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 21-27.	0.4	83
333	Stem cell transplantation in chronic lymphocytic leukaemia – steering a safe course over shifting sands. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 109-119.	1.7	2
334	How I treat CLL up front. <i>Blood</i> , 2010, 115, 187-197.	1.4	183
335	Chronic lymphocytic leukemia: planning for an aging population. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1389-1394.	2.4	34
336	Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). <i>Blood</i> , 2010, 116, 1376-1376.	1.4	1
337	A Phase II Trial of Sequential Treatment with Cyto-reductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report.. <i>Blood</i> , 2010, 116, 3480-3480.	1.4	2
338	Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study. <i>Blood</i> , 2010, 116, 697-697.	1.4	20
339	An Immunohistochemical Score Based On CD68 and FOXP3 Expression In the Tumour Microenvironment at Diagnosis Defines Prognostic Groups In Both Early and Advanced Stage Classical Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 750-750.	1.4	3
340	TNFRSF14 and EZH2 Mutations, Chr2p Gain and Copy Number Changes Targeting Genes Whose Proteins Interact with the Microenvironment In Transformed Follicular Lymphoma. <i>Blood</i> , 2010, 116, 799-799.	1.4	1
341	Defective LFA-1 Mediated T Cell Motility In Chronic Lymphocytic Leukemia Is Mediated by Defects In the Rho GTPase Signaling Pathway. <i>Blood</i> , 2010, 116, 914-914.	1.4	0
342	Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997. <i>Blood</i> , 2010, 116, 924-924.	1.4	1

#	ARTICLE	IF	CITATIONS
343	Functional Screening Studies Identify Combinational Activity of PD-L1 and CD200 In Mediating Dysfunctional T Cell Immunological Synapse Formation In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 696-696.	1.4	0
344	Autocrine IL6/STAT3 Signaling Enhances Survival of Chronic Lymphocytic Leukaemia Cells. <i>Blood</i> , 2010, 116, 3598-3598.	1.4	0
345	Targeting Chronic Lymphocytic Leukemia with Cord Blood NK Cells In NSG Model. <i>Blood</i> , 2010, 116, 2453-2453.	1.4	0
346	Differential Gene Expression Profile Identifies Defects and Abnormalities In Infiltrating T Cells In Patients with Follicular Lymphoma at Diagnosis. <i>Blood</i> , 2010, 116, 141-141.	1.4	2
347	Potential of Bortezomib-Induced Killing of Lymphoma Cells by Inhibition of Autophagy and Prevention of I- β Degradation. <i>Blood</i> , 2010, 116, 116-116.	1.4	1
348	Prospective Use of a Triple FISH Probe to Predict sMDS/AML Following High Dose Therapy with Autologous Stem Cell Rescue for Lymphoma.. <i>Blood</i> , 2010, 116, 3459-3459.	1.4	0
349	A Single-Centre Analysis by Intention to Treat with High Dose Chemotherapy and Autologous Stem Cell Rescue Following Second-Line Treatment In Patients with Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 2388-2388.	1.4	0
350	Physician Scientists In Hematology: Hematologists' Experiences of Research and Recruitment to Academia - A Mixed Methods, Qualitative Approach. <i>Blood</i> , 2010, 116, 2570-2570.	1.4	2
351	β 4- <i>TCL1</i> mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6250-6255.	7.1	112
352	5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen. <i>Journal of Clinical Oncology</i> , 2009, 27, 5208-5212.	1.6	147
353	Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2009, 69, 5424-5432.	0.9	160
354	Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens. <i>Journal of Immunological Methods</i> , 2009, 348, 95-100.	1.4	6
355	Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. <i>Annals of Hematology</i> , 2009, 88, 121-132.	1.8	51
356	Rediscovering alemtuzumab: current and emerging therapeutic roles. <i>British Journal of Haematology</i> , 2009, 144, 818-831.	2.5	59
357	Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. <i>British Journal of Haematology</i> , 2009, 146, 574-576.	2.5	20
358	Array-based DNA methylation profiling in follicular lymphoma. <i>Leukemia</i> , 2009, 23, 1858-1866.	7.2	65
359	Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009, 33, 368-376.	0.8	23
360	Stem Cell Transplantation in Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 53-58.	2.0	49

#	ARTICLE	IF	CITATIONS
361	Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma. <i>Haematologica</i> , 2009, 94, 148-150.	3.5	18
362	Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. <i>Blood</i> , 2009, 113, 3553-3557.	1.4	129
363	Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. <i>Blood</i> , 2009, 113, 2298-2301.	1.4	75
364	Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. <i>Blood</i> , 2009, 114, 3909-3916.	1.4	190
365	Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. <i>Blood</i> , 2009, 114, 4713-4720.	1.4	215
366	One step back but 2 steps forward. <i>Blood</i> , 2009, 114, 3359-3360.	1.4	8
367	Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. <i>Haematologica</i> , 2009, 94, 1198-1202.	3.5	56
368	Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT.. <i>Blood</i> , 2009, 114, 1190-1190.	1.4	1
369	Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2R β null (NSG) Mice as a Model.. <i>Blood</i> , 2009, 114, 2370-2370.	1.4	1
370	An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).. <i>Blood</i> , 2009, 114, 3428-3428.	1.4	6
371	Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712.. <i>Blood</i> , 2009, 114, 539-539.	1.4	8
372	Impaired Natural Killer Cells Immune Synapse Formation in Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2663-2663.	1.4	0
373	Spontaneous in Vitro Death of CLL Cells Can Be Prevented by Mitochondrial Stabilization Via CD160 Signaling.. <i>Blood</i> , 2009, 114, 4372-4372.	1.4	0
374	Expression of Surface IgG Is High in Chronic Lymphocytic Leukaemia, and Co-Expression with IgM Confers a Worse Prognosis.. <i>Blood</i> , 2009, 114, 4371-4371.	1.4	0
375	CD160 Expression in B-Cell Lymphoproliferative Disorders: Derivation and Validation of a New Three-Antigen Scoring System Improving Diagnostic Precision in B-Cell Malignancies.. <i>Blood</i> , 2009, 114, 4382-4382.	1.4	0
376	Ex Vivo IL-2 Expansion of CB-NK Cells Promotes Synergistic LFA-1 and CD2 Engagement at the NK Cell Lytic Immune Synapse; Implications for Adoptive CB-NK Cell Therapy in Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 3029-3029.	1.4	0
377	Vaccine therapy and chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 421-436.	1.7	8
378	Stem Cell Transplantation for Non-Hodgkin's Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 1051-1079.	2.2	19

#	ARTICLE	IF	CITATIONS
379	Role of Allogeneic Hematopoietic Stem-Cell Transplantation in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2008, 26, 4864-4865.	1.6	1
380	Molecular Profiling in CLL. Hematology American Society of Hematology Education Program, 2008, 2008, 444-449.	2.5	28
381	Biologic prognostic markers and their application in clinical trials and management of chronic lymphocytic leukaemia patients. Expert Opinion on Medical Diagnostics, 2008, 2, 101-112.	1.6	1
382	Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood, 2008, 111, 3137-3144.	1.4	45
383	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood, 2008, 112, 1923-1930.	1.4	282
384	Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood, 2008, 111, 2797-2805.	1.4	79
385	Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood, 2008, 111, 2790-2796.	1.4	28
386	Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood, 2008, 112, 568-575.	1.4	345
387	Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood, 2008, 111, 5101-5108.	1.4	65
388	Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation, 2008, 118, 2427-37.	8.2	487
389	Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL-001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 2104-2104.	1.4	5
390	Compared to Adult Peripheral Blood T Cells, Cord Blood T Cells Show Enhanced Immunological Recognition of Chronic Lymphocytic Leukemia Tumor Cells.. Blood, 2008, 112, 2333-2333.	1.4	3
391	Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort. Blood, 2008, 112, 3125-3125.	1.4	2
392	Lenalidomide Repairs Suppressed T Cell Immunological Synapse Formation in Follicular Lymphoma. Blood, 2008, 112, 885-885.	1.4	1
393	Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 972-972.	1.4	6
394	Spleen Tyrosine Kinase (SYK) Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. Blood, 2008, 112, 543-543.	1.4	0
395	Defective T Cell Migration in Chronic Lymphocytic Leukemia Is Repaired by Lenalidomide. Blood, 2008, 112, 3117-3117.	1.4	0
396	Extended Focal Imaging Reveals An Improved Gauge of Angiogenic Activity and Highlights the Role of Angiogenesis in Survival and Time to Transformation in Follicular Lymphoma. Blood, 2008, 112, 2822-2822.	1.4	0

#	ARTICLE	IF	CITATIONS
397	Dual Action of CD160 on CLL Cells: Giving Life to Prepare for Death!.. Blood, 2008, 112, 2088-2088.	1.4	0
398	A Mouse Model for Immunotherapeutic Reversal of Leukemia-Induced T Cell Dysfunction. Blood, 2008, 112, 30-30.	1.4	0
399	Differential Gene Expression Profile Identifies the Nature of T Cell Defects in AML Patients at Diagnosis.. Blood, 2008, 112, 1186-1186.	1.4	0
400	Ex Vivo Expansion of Cord Blood Natural Killer Cells Overcomes Impaired Immune Synapse Formation and Effector Function in Acute Myeloid Leukemia. Blood, 2008, 112, 2905-2905.	1.4	0
401	Plasma Alemtuzumab Levels at End of Treatment Correlate with Response and Response Duration in Patients with CLL Receiving Treatment for Residual Disease.. Blood, 2008, 112, 2109-2109.	1.4	0
402	Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. Blood, 2007, 109, 3989-3997.	1.4	48
403	How I treat indolent lymphoma. Blood, 2007, 109, 4617-4626.	1.4	100
404	Long-Term Survival after Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission. Biology of Blood and Marrow Transplantation, 2007, 13, 1057-1065.	2.0	61
405	Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology, 2007, 25, 799-804.	1.6	320
406	Stem-cell transplantation in chronic lymphocytic leukaemia. Best Practice and Research in Clinical Haematology, 2007, 20, 513-527.	1.7	12
407	Emerging therapy for chronic lymphocytic leukaemia. British Journal of Haematology, 2007, 139, 635-644.	2.5	18
408	Transplantation in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 2007, 2, 56-63.	2.3	1
409	Determining the Mechanism of Transformation of Follicular Lymphoma into Diffuse Large B Cell Lymphoma.. Blood, 2007, 110, 181-181.	1.4	5
410	Bax Degradation Activity Is a Novel Poor Prognosis Marker of Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3087-3087.	1.4	0
411	Temporal Proteomic Analysis of CLL B Cell Response to Antigen Receptor Stimulation.. Blood, 2007, 110, 1134-1134.	1.4	0
412	SAGE Analysis Demonstrates Increased Expression of TOSO Contributing to Fas Mediated Resistance in CLL.. Blood, 2007, 110, 1121-1121.	1.4	0
413	Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L.. Blood, 2007, 110, 740-740.	1.4	0
414	High Frequency of Surface Immunoglobulin IgG in B-Cell Chronic Lymphocytic Leukaemia.. Blood, 2007, 110, 4685-4685.	1.4	0

#	ARTICLE	IF	CITATIONS
415	CD3+/CD56+ Cells, but Not Natural Killer T Cells, Are Increased in Peripheral Blood of Untreated Patients with Leukemia.. Blood, 2007, 110, 1815-1815.	1.4	3
416	Impaired Actin Polymerization Results in Defective Immunological Synapse Formation in T Cells in Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 338-338.	1.4	2
417	CLL Cell Proliferation and IL-6 Production Are Regulated by CD160 - MHC Class I Interactions Offering New Therapeutic Targets.. Blood, 2007, 110, 1126-1126.	1.4	0
418	Angiogenesis Assessed in Tissue Microarrays of Diagnostic Follicular Lymphoma Correlates with Outcome.. Blood, 2007, 110, 2609-2609.	1.4	0
419	A Novel Non-Invasive Method of Detecting Galactomannan in Suspected Pulmonary Aspergillosis.. Blood, 2007, 110, 3862-3862.	1.4	5
420	Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy. Journal of Clinical Oncology, 2006, 24, 437-443.	1.6	233
421	Vaccine- and Immune-Based Therapy in Chronic Lymphocytic Leukemia. Seminars in Oncology, 2006, 33, 220-229.	2.2	10
422	Predictors of Improved Progression-Free Survival After Nonmyeloablative Allogeneic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2006, 12, 1056-1064.	2.0	110
423	The potential value of very intensive therapy with autologous bone marrow rescue in the treatment of malignant lymphomas. Hematological Oncology, 2006, 5, 281-293.	1.7	24
424	Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders. Clinical Infectious Diseases, 2006, 43, 16-24.	5.8	255
425	Long-Term Follow-Up After Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome: Late CNS Relapses Despite Graft-Versus-Host Disease. Journal of Clinical Oncology, 2006, 24, e23-e25.	1.6	17
426	Number of CD4+ Cells and Location of Forkhead Box Protein P3â€œPositive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome. Journal of Clinical Oncology, 2006, 24, 5052-5059.	1.6	210
427	Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2778-2778.	1.4	2
428	Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients (pts) with CLL.. Blood, 2006, 108, 2839-2839.	1.4	3
429	Stromal Cells Protect B-CLL Cells from Killing by Antigen-Specific Cytotoxic T Cells.. Blood, 2006, 108, 2814-2814.	1.4	5
430	Increased CD68 and Decreased CD4 Expressing Cells in Tissue Microarray (TMA) in Diagnostic Lymph Node Biopsies Are Associated with Poor Outcome in CLL/SLL.. Blood, 2006, 108, 2781-2781.	1.4	0
431	Utilisation of Stem Cell Transplantation for Lymphoplasmacytic Lymphoma in the UK.. Blood, 2006, 108, 2980-2980.	1.4	0
432	Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.. Blood, 2006, 108, 3041-3041.	1.4	0

#	ARTICLE	IF	CITATIONS
433	Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression.. Blood, 2006, 108, 2774-2774.	1.4	0
434	Dynamic Assessment of Apoptosis for In Vitro Design of Bortezomib Combination Therapies for Lymphoid Malignancies.. Blood, 2006, 108, 2494-2494.	1.4	0
435	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood, 2005, 105, 1810-1814.	1.4	280
436	Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood, 2005, 106, 4389-4396.	1.4	208
437	Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. Blood, 2005, 105, 2235-2238.	1.4	13
438	Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leukemia Research, 2005, 29, 1253-1257.	0.8	95
439	Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. British Journal of Haematology, 2005, 129, 499-510.	2.5	48
440	Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. British Journal of Haematology, 2005, 131, 185-192.	2.5	13
441	The evolving role of Alemtuzumab in management of patients with CLL. Leukemia, 2005, 19, 2147-2152.	7.2	31
442	The role of the tumor microenvironment in hematological malignancies and implication for therapy. Frontiers in Bioscience - Landmark, 2005, 10, 1581.	3.0	50
443	Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. Journal of Clinical Investigation, 2005, 115, 1797-1805.	8.2	259
444	Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy. Clinical Cancer Research, 2005, 11, 4430-4436.	7.0	153
445	Salvage Therapy for CLL and the Role of Stem Cell Transplantation. Hematology American Society of Hematology Education Program, 2005, 2005, 292-298.	2.5	19
446	Fludarabine and Alemtuzumab Versus Fludarabine and Rituximab in the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from a Phase II Study.. Blood, 2005, 106, 5046-5046.	1.4	3
447	Successful Generation of Cytotoxic T-Cells That Kill CLL Cells Using Heteroclitic Peptides Is Independent of the Native Peptide Binding Affinity to HLA-A*0201.. Blood, 2005, 106, 54-54.	1.4	3
448	High Levels of Early Donor Chimerism and Treatment-Responsive Disease Predict Improved Progression-Free Survival Following Non-Myeloablative Transplantation for Advanced CLL.. Blood, 2005, 106, 560-560.	1.4	5
449	Patients (Pts) Surviving Haploidentical Stem Cell Transplantation (SCT) after Ex Vivo Costimulatory Blockade To Induce Anergy Experience Few Long-Term Complications.. Blood, 2005, 106, 599-599.	1.4	2
450	HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.. Blood, 2005, 106, 835-835.	1.4	3

#	ARTICLE	IF	CITATIONS
451	In Vivo Demonstration of Donor Idiotype Specific T Cells That Kill Primary CLL Cells Post Allogeneic Transplant.. Blood, 2005, 106, 62-62.	1.4	0
452	Discrimination of Long and Short Survival in Follicular Lymphoma (FL) Patients by Incidence of FOXP3 and Perifollicular Incidence of CD4 and CD7 Using Immunohistochemistry on Tissue Microarray (TMA) of Diagnostic Lymph Nodes (LN).. Blood, 2005, 106, 603-603.	1.4	1
453	CLL Cells in TCL1 Transgenic Mice Induce Similar Defects in CD4 and CD8 T Cells to Those Observed in Patients with CLL.. Blood, 2005, 106, 50-50.	1.4	1
454	Expression of T Cell Co-Stimulator (ICOS) and Its Ligand and Disease Progression in B-Cell Chronic Lymphocytic Leukemia.. Blood, 2005, 106, 2943-2943.	1.4	1
455	CD40 activation: lessons for HIV immunotherapy from malignancies?. Journal of HIV Therapy, 2005, 10, 51-5.	0.6	0
456	Autologous Bone Marrow Transplantation for Marginal Zone Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2004, 45, 315-320.	1.3	15
457	FLT3 mutations in childhood acute lymphoblastic leukemia. Blood, 2004, 103, 3544-3546.	1.4	235
458	CD40 activation: potential for specific immunotherapy in B-CLL. Annals of Oncology, 2004, 15, 853-857.	1.2	25
459	Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders. Leukemia, 2004, 18, 953-961.	7.2	22
460	Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. Leukemia Research, 2004, 28, 139-147.	0.8	20
461	ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2004, 351, 893-901.	27.0	824
462	Death of follicular lymphoma cells—the long and the short of it. Blood, 2004, 103, 374-374.	1.4	0
463	Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis. Blood, 2004, 103, 4602-4609.	1.4	42
464	Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood, 2004, 104, 4002-4009.	1.4	37
465	Mapping Low Molecular Weight Plasma Proteome of Chronic Lymphoblastic Leukemia Patients Using MALDI-TOF Mass Spectrometry.. Blood, 2004, 104, 1910-1910.	1.4	5
466	Quantitative Analysis of Minimal Residual Disease at the Completion of Induction Therapy Predicts Relapse in Children with B-Lineage Acute Lymphoblastic Leukemia in DFCI ALL Consortium Protocol 95-01.. Blood, 2004, 104, 323-323.	1.4	2
467	Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997.. Blood, 2004, 104, 3487-3487.	1.4	8
468	Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD) Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone.. Blood, 2004, 104, 730-730.	1.4	5

#	ARTICLE	IF	CITATIONS
469	Distinct VDJ-H Gene Usage between Mutated and Unmutated Patients in B-CLL: Implications for Pathogenesis and Correlation with Clinical Outcome.. Blood, 2004, 104, 970-970.	1.4	0
470	Temporal Gene Expression after BCR-Crosslinking Based upon Zap70 Related Genomic Features.. Blood, 2004, 104, 2795-2795.	1.4	0
471	A Phase II Study of Xcellerated T Cellsâ„¢ in Patients with Relapsed or Refractory Indolent Non-Hodgkinâ€™s Lymphoma (NHL).. Blood, 2004, 104, 4640-4640.	1.4	0
472	Somatic Hypermutation Does Not Increase the Binding Affinity of Ig Derived Peptides to MHC Class I or II - Implications for Ig Peptide Vaccination Strategies.. Blood, 2004, 104, 960-960.	1.4	0
473	Molecular Analysis of T-Cell Receptor Gene Rearrangements in Children with T-Cell Acute Lymphoblast Leukemia on DFCI ALL Consortium Protocol 95-01.. Blood, 2004, 104, 1084-1084.	1.4	0
474	CD38 Compared with ZAP-70 or Immunoglobulin Mutation Status as Predictor of Disease Progression in Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 2805-2805.	1.4	1
475	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. Blood, 2004, 104, 185-185.	1.4	0
476	Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Long Term Follow up of Two Sequential Trials with Standard Dose and High Dose CHOP Induction.. Blood, 2004, 104, 5243-5243.	1.4	0
477	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. Blood, 2004, 104, 300-300.	1.4	2
478	Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL.. Blood, 2004, 104, 4841-4841.	1.4	2
479	Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment.. Blood, 2004, 104, 956-956.	1.4	7
480	Gene Expression Profiling Identifies Similar CD4+ and CD8+ T Cell Defects in TCL1 Transgenic Mice after Development of CLL to Those Observed in Patients with CLL.. Blood, 2004, 104, 180-180.	1.4	0
481	Reprogramming the Transcriptional Response of Chronic Lymphocytic Leukemia (CLL) Cells: Influencing the Temporal Gene Regulatory Network.. Blood, 2004, 104, 1128-1128.	1.4	0
482	Cell Contact with CLL Cells Induces Defects in T Cell Differentiation and Effector Pathways: Impact of Silencing Specific Cytokine Production.. Blood, 2004, 104, 955-955.	1.4	0
483	Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma. Bone Marrow Transplantation, 2003, 32, 681-686.	2.4	7
484	Sustained complete remission of CLL associated with the use of a Chinese herbal extract: case report and mechanistic analysis. Leukemia Research, 2003, 27, 859-863.	0.8	10
485	Indolent B-Cell Malignancies: Immune Recognition and Antiself. Leukemia and Lymphoma, 2003, 44, S77-S83.	1.3	0
486	Cytotoxic T Cell Responses Against Immunoglobulin in Malignant and Normal B Cells: Implications for Tumor Immunity and Autoimmunity. Current Pharmaceutical Design, 2003, 9, 1889-1903.	1.9	13

#	ARTICLE	IF	CITATIONS
487	Role of autologous stem cell transplantation in chronic lymphocytic leukemia. <i>Current Opinion in Hematology</i> , 2003, 10, 306-311.	2.5	2
488	Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. <i>Blood</i> , 2003, 102, 4520-4526.	1.4	55
489	T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. <i>Blood</i> , 2002, 100, 167-173.	1.4	78
490	Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. <i>Blood</i> , 2002, 100, 2123-2131.	1.4	113
491	Monitoring disease in lymphoma and CLL patients using molecular techniques. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 179-195.	1.7	12
492	Immunotherapy in the B-cell lymphomas. <i>Cytotherapy</i> , 2002, 4, 439-440.	0.7	0
493	Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 601-607.	2.0	26
494	Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 9-16.	2.0	39
495	Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 429-434.	2.0	11
496	Autologous hematopoietic transplantation for low-grade lymphomas. <i>Cytotherapy</i> , 2002, 4, 205-215.	0.7	6
497	Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival. <i>Journal of Clinical Oncology</i> , 2002, 20, 1288-1294.	1.6	317
498	Real-time polymerase chain reaction in multiple myeloma. <i>Experimental Hematology</i> , 2002, 30, 529-536.	0.4	24
499	Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. <i>Experimental Hematology</i> , 2002, 30, 703-710.	0.4	30
500	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2002, 117, 828-834.	2.5	131
501	Cd40 Ligand Therapy of Lymphoma Patients. <i>Journal of Clinical Oncology</i> , 2001, 19, 4351-4353.	1.6	15
502	CD6+ Donor Marrow T-Cell Depletion as the Sole Form of Graft-Versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Bone Marrow Transplant From Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2001, 19, 1152-1159.	1.6	49
503	Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen A2 binding residues. <i>Blood</i> , 2001, 98, 2999-3005.	1.4	57
504	T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. <i>Blood</i> , 2001, 98, 934-939.	1.4	193

#	ARTICLE	IF	CITATIONS
505	Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients. <i>Journal of Clinical Oncology</i> , 2001, 19, 3280-3287.	1.6	209
506	A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2. <i>British Journal of Haematology</i> , 2001, 113, 455-460.	2.5	32
507	A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. <i>Experimental Hematology</i> , 2001, 29, 183-193.	0.4	64
508	Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. <i>Cancer Research</i> , 2001, 61, 4761-5.	0.9	31
509	CD34 selection as a stem cell purging strategy for neuroblastoma: Preclinical and clinical studies. <i>Medical and Pediatric Oncology</i> , 2000, 35, 677-682.	1.0	38
510	Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. <i>Nature Medicine</i> , 2000, 6, 667-672.	30.7	163
511	Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 241-253.	2.0	85
512	Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. <i>Blood</i> , 2000, 95, 2651-8.	1.4	30
513	Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. <i>Cancer Journal (Sudbury, Mass)</i> , 2000, 6, 146-50.	2.0	19
514	Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3128-3135.	1.6	180
515	Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. <i>Blood</i> , 1999, 94, 3325-3333.	1.4	319
516	Transplantation of Anergic Histoincompatible Bone Marrow Allografts. <i>New England Journal of Medicine</i> , 1999, 340, 1704-1714.	27.0	428
517	Human Non-Germinal Center B Cell Interleukin (IL)-12 Production Is Primarily Regulated by T Cell Signals CD40 Ligand, Interferon γ , and IL-10: Role of B Cells in the Maintenance of α CD4 T Cell Responses. <i>Journal of Experimental Medicine</i> , 1999, 189, 1-12.	8.5	138
518	Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. <i>Journal of Molecular Medicine</i> , 1999, 77, 259-265.	3.9	30
519	Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 262-268.	2.0	68
520	Stem cell transplantation for indolent lymphoma. <i>Current Opinion in Hematology</i> , 1999, 6, 388.	2.5	2
521	A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , 1999, 5, 2392-8.	7.0	38
522	Stem-cell transplantation for indolent lymphoma. <i>Seminars in Hematology</i> , 1999, 36, 18-25.	3.4	3

#	ARTICLE	IF	CITATIONS
523	Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. <i>Blood</i> , 1999, 94, 3325-33.	1.4	82
524	No evidence for MUC 1-induced apoptosis. <i>Nature Medicine</i> , 1998, 4, 1093-1093.	30.7	3
525	Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor- β gene promoter. <i>Tissue Antigens</i> , 1998, 52, 359-367.	1.0	227
526	Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies. <i>Current Opinion in Oncology</i> , 1998, 10, 542-547.	2.4	14
527	High Dose Therapy and Autologous Stem Cell Transplantation in Follicular non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1998, 28, 219-230.	1.3	18
528	High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.. <i>Journal of Clinical Oncology</i> , 1998, 16, 13-18.	1.6	174
529	Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. <i>Blood</i> , 1998, 91, 244-51.	1.4	33
530	Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. <i>Blood</i> , 1998, 91, 4496-503.	1.4	11
531	In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Energy But Is Insufficient to Induce Significant T-Cell Proliferation. <i>Blood</i> , 1997, 90, 4297-4306.	1.4	96
532	Ex Vivo Generation of Human Anti-Pre-B Leukemia-Specific Autologous Cytolytic T Cells. <i>Blood</i> , 1997, 90, 549-561.	1.4	125
533	A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. <i>Leukemia</i> , 1997, 11, 1793-1798.	7.2	99
534	Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. , 1997, 56, 45-51.		18
535	CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.. <i>Journal of Clinical Investigation</i> , 1997, 100, 2757-2765.	8.2	308
536	Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. <i>Blood</i> , 1997, 89, 3806-16.	1.4	23
537	Bone marrow transplantation for low-grade B-cell malignancies. <i>Current Opinion in Oncology</i> , 1997, 9, 117-21.	2.4	0
538	Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. <i>Blood</i> , 1997, 90, 549-61.	1.4	23
539	Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. <i>Journal of Immunology</i> , 1997, 159, 3156-67.	0.8	44
540	Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. <i>Blood</i> , 1997, 90, 4212-21.	1.4	20

#	ARTICLE	IF	CITATIONS
541	In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. <i>Blood</i> , 1997, 90, 4297-306.	1.4	20
542	Minimal residual disease in non-Hodgkin's lymphoma. <i>Biomedicine and Pharmacotherapy</i> , 1996, 50, 451-458.	5.6	6
543	B7-mediated costimulation and the immune response. <i>Blood Reviews</i> , 1996, 10, 111-127.	5.7	114
544	Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. <i>Nature Medicine</i> , 1996, 2, 1367-1370.	30.7	164
545	Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation.. <i>Journal of Experimental Medicine</i> , 1996, 184, 365-376.	8.5	82
546	Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. <i>Blood</i> , 1996, 87, 4887-93.	1.4	24
547	Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. <i>Blood</i> , 1996, 88, 41-8.	1.4	46
548	High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. <i>Blood</i> , 1996, 88, 2780-6.	1.4	22
549	CTLA4 mediates antigen-specific apoptosis of human T cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 811-815.	7.1	312
550	Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 8200-8204.	7.1	200
551	Attainment of molecular remission: a worthwhile goal?. <i>Journal of Clinical Oncology</i> , 1994, 12, 1532-1534.	1.6	23
552	CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy.. <i>Journal of Experimental Medicine</i> , 1994, 180, 1665-1673.	8.5	109
553	Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. <i>Science</i> , 1994, 266, 1039-1042.	12.6	303
554	Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. <i>Current Opinion in Immunology</i> , 1994, 6, 797-807.	5.5	137
555	The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. <i>Blood</i> , 1994, 84, 1402-7.	1.4	24
556	Detection of minimal residual disease in patients with lymphomas using the polymerase chain reaction. <i>Important Advances in Oncology</i> , 1994, , 117-29.	0.2	1
557	Bone Marrow Purging for Autologous Bone Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 1993, 11, 141-148.	1.3	14
558	Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.. <i>Journal of Experimental Medicine</i> , 1993, 178, 2185-2192.	8.5	363

#	ARTICLE	IF	CITATIONS
559	Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation. <i>Science</i> , 1993, 262, 909-911.	12.6	874
560	Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 11059-11063.	7.1	208
561	Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 6586-6590.	7.1	519
562	Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. <i>Blood</i> , 1993, 82, 1366-76.	1.4	28
563	Monitoring minimal residual disease. <i>Seminars in Oncology</i> , 1993, 20, 143-55.	2.2	6
564	Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. <i>Blood</i> , 1993, 81, 3449-57.	1.4	53
565	The gene for B7, a costimulatory signal for T-cell activation, maps to chromosomal region 3q13.3-3q21. <i>Blood</i> , 1992, 79, 489-94.	1.4	7
566	Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. <i>Blood</i> , 1992, 80, 1083-9.	1.4	8
567	Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 1991, 325, 1525-1533.	27.0	678
568	Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7.. <i>Journal of Experimental Medicine</i> , 1991, 174, 625-631.	8.5	332
569	B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 6575-6579.	7.1	424
570	Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. <i>Blood</i> , 1991, 77, 1837-44.	1.4	21
571	Autologous Bone-Marrow Transplantation in Acute Lymphoblastic Leukaemia: 1980â€“89. <i>Leukemia and Lymphoma</i> , 1990, 1, 157-162.	1.3	4
572	The Role of Growth Factors in Bone-Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 1990, 1, 87-93.	1.3	5
573	Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. <i>Lancet</i> , The, 1990, 335, 434-437.	13.7	205
574	Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy.. <i>Journal of Clinical Oncology</i> , 1989, 7, 1621-1629.	1.6	132
575	Plasma from patients with severe Lassa fever profoundly modulates f-met-leu-phe induced superoxide generation in neutrophils. <i>British Journal of Haematology</i> , 1989, 73, 152-157.	2.5	26
576	Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. <i>Blood</i> , 1989, 73, 340-4.	1.4	38

#	ARTICLE	IF	CITATIONS
577	GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease. <i>Bone Marrow Transplantation</i> , 1989, 4, 49-54.	2.4	58
578	The role of autologous bone marrow transplantation in the treatment of malignant disease. <i>Blood Reviews</i> , 1987, 1, 193-200.	5.7	6
579	Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis. <i>Current Biomarker Findings</i> , 0, , 17.	0.4	1